A Randomized, Double-blind, Placebo-controlled Phase Ⅰ/Ⅱ Clinical Study to Evaluate the Safety, Tolerability and Immunogenicity of SCTV01C in Healthy Population Aged ≥18 Years Previously Unvaccinated Against COVID-19
Latest Information Update: 13 Feb 2024
Price :
$35 *
At a glance
- Drugs SCTV 01C (Primary)
- Indications COVID 2019 infections
- Focus Adverse reactions; Pharmacodynamics
- Sponsors Sinocelltech
- 06 Feb 2024 Status changed from recruiting to completed.
- 14 Dec 2021 New trial record
- 12 Dec 2021 Status changed from not yet recruiting to recruiting.